Future Directions with DNA Repair Inhibitors: A Roadmap for Disruptive Approaches to Cancer Therapy

DNA Repair in Cancer Therapy

Volumn , Issue , 2012, Pages 301-310

  Kelley, Mark R ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80054761771     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-384999-1.10014-9     Document Type: Chapter

References (28)

1. Vens C., Begg A.C. Targeting base excision repair as a sensitization strategy in radiotherapy. Semin Radiat Oncol 2010, 20(4):241-249.
2. Rowe B.P., Glazer P.M. Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms. Breast Cancer Res 2010, 12(2):203.
3. Reed A.M., Fishel M.L., Kelley M.R. Small-molecule inhibitors of proteins involved in base excision repair potentiate the anti-tumorigenic effect of existing chemotherapeutics and irradiation. Future Oncol 2009, 5(5):713-726.
4. Kelley M.R., Fishel M.L. DNA repair proteins as molecular targets for cancer therapeutics. Anticancer Agents Med Chem 2008, 8(4):417-425.
5. Helleday T., Petermann E., Lundin C., Hodgson B., Sharma R.A. DNA repair pathways as targets for cancer therapy. Nature Rev 2008, 8(3):193-204.
6. Sanchez-Perez I. DNA repair inhibitors in cancer treatment. Clin Transl Oncol 2006, 8(9):642-646.
7. Gullotta F., De Marinis E., Ascenzi P., di Masi A. Targeting the DNA double strand breaks repair for cancer therapy. Curr Med Chem 2010, 17(19):2017-2048.
8. Maxmen A. Beyond PARP inhibitors: agents in pipelines target DNA repair mechanisms. J Natl Cancer Inst 2010, 102(15):1110-1111.
9. Moeller B.J., Arap W., Pasqualini R. Targeting synthetic lethality in DNA damage repair pathways as an anti-cancer strategy. Curr Drug Targets 2010, 11(10):1336-1340.
10. Chan N., Bristow R.G. Contextual synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair. Clin Cancer Res 2010, 16(18):4553-4560.
11. Ali M., Telfer B.A., McCrudden C., et al. Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo?. Clin Cancer Res 2009, 15(19):6106-6112.
12. Aziz K., Nowsheen S., Georgakilas A.G. Nanotechnology in cancer therapy: targeting the inhibition of key DNA repair pathways. Curr Mol Med 2010, 10(7):626-639.
13. Iglehart J.D., Silver D.P. Synthetic lethality - a new direction in cancer-drug development. N Engl J Med 2009, 361(2):189-191.
14. Ho A.Y., Atencio D.P., Peters S., et al. Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. Int J Radiat Oncol Biol Phys 2006, 65(3):646-655.
15. Abbotts R., Madhusudan S. Human AP endonuclease 1 (APE1): From mechanistic insights to druggable target in cancer. Cancer Treat Rev 2010, 36(5):425-435.
16. Plummer R. Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target. Clin Cancer Res 2010, 16(18):4527-4531.
17. Drew Y., Plummer R. The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer. Curr Opin Obstet Gynecol 2010, 22(1):67-71.
18. Mitra S., Hazra T.K., Roy R., et al. Complexities of DNA base excision repair in mammalian cells. Mol Cells 1997, 7(3):305-312.
19. Guillet M., Boiteux S. Endogenous DNA abasic sites cause cell death in the absence of Apn1, Apn2 and Rad1/Rad10 in. Saccharomyces cerevisiae. EMBO J 2002, 21(11):2833-2841.
20. Chan K.K., Zhang Q.M., Dianov G.L. Base excision repair fidelity in normal and cancer cells. Mutagenesis 2006, 21(3):173-178.
21. Thompson L.H., West M.G. XRCC1 keeps DNA from getting stranded. Mutat Res 2000, 459(1):1-18.
22. Neher T.M., Shuck S.C., Liu J.Y., Zhang J.T., Turchi J.J. Identification of novel small molecule inhibitors of the XPA protein using in silico based screening. ACS Chem Biol 2010, 5(10):953-965.
23. Shuck S.C., Turchi J.J. Targeted inhibition of replication protein A reveals cytotoxic activity, synergy with chemotherapeutic DNA-damaging agents, and insight into cellular function. Cancer Res 2010, 70(8):3189-3198.
24. Shuck S.C., Short E.A., Turchi J.J. Eukaryotic nucleotide excision repair: from understanding mechanisms to influencing biology. Cell Res 2008, 18(1):64-72.
25. Earley J.N., Turchi J.J. Interrogation of nucleotide excision repair capacity: impact on platinum-based cancer therapy. Antioxid Redox Signal 2011, 23. January [Epub ahead of print].
26. de Bono J.S., Ashworth A. Translating cancer research into targeted therapeutics. Nature 2010, 467(7315):543-549.
27. Jubb A.M., Buffa F.M., Harris A.L. Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis. J Cell Mol Med 2010, 14(1-2):18-29.
28. Drew Y., Plummer R. PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications. Drug Resist Updat 2009, 12(6):153-156.